References
1. Yamanaka S. Pluripotent stem cell-based cell therapy-promise and challenges. Cell Stem Cell. Oct 1 2020;27(4):523–531. doi:10.1016/j.stem.2020.09.014.
2. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. Nov 30 2007;131(5):861–72. doi:10.1016/j.cell.2007.11.019.
3. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson’s disease. Lancet. Jan 20 2024;403(10423):293–304. doi:10.1016/S0140-6736(23)01478-2.
4. Sawamoto N, Doi D, Nakanishi E, et al. Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature. May 2025;641(8064):971–977. doi:10.1038/s41586-025-08700-0.
5. Tabar V, Sarva H, Lozano AM, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease. Nature. May 2025;641(8064):978–983. doi:10.1038/s41586-025-08845-y.
6. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson’s disease. Nat Neurosci. Jul 2002;5(7):627–8. doi:10.1038/nn863.
7. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol. Sep 2003;54(3):403–14. doi:10.1002/ana.10720.
Recommended Citation
Kheolamai, Pakpoom.
2025
The End of the Beginning of Human Pluripotent Stem Cell Therapy.
Asian Medical Journal and Alternative Medicine. 25,
2 (Aug. 2025 ), 2-3.
Available at: https://doi.org/10.70933/2773-9465.1019
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
